References
1. National Center Information Cancer. 2018. Republic of Korea: Ministry of Health and Welfare Available from :
https://www.cancer.go.kr. Accessed Feb 13, 2019.
5. Kim YH, Kim YT, Kim HK, Park IG, Wu HG, Song SY, et al. Lung cancer clinical practice guideline Seoul: Korean Association for the Study of Lung Cancer; 2011. p. 1–141.
6. The Korea Academy of Tuberculosis and Respiratory Disease. Pneumology Seoul: Koonja; 2007. p. 597–634.
7. Korean Oncology Nursing Society. Oncology Nursing : Treatment and Care 2nd ed.th ed. Seoul: FOR NURSE; 2014. p. 50–70.
8. Baek SM. Related Factors on Quality of life in Patients with Lung cancer [master’s thesis] Gwangju: Chonnam National University; 2011.
9. Hong MN, Shim SH, Yoon SH, Choi JY, Kim YS. Development and Validity Test on Preliminary Critical Pathway of Integrative Medicine for Lung Cancer Patients Treated with Chemotherapy. J Int Korean Med 2017;38(6):917–929.
10. Jung HJ, Kim JD. The role of Korean Medicine for Treatment and Management gor Lung cancer. J of Kor Traditional Oncology 2015;20(1):45–54.
11. Chang SB, Lee TW, Kim S, Yoo IY, Kim IS, Kang KH, et al. A study of complementary and aiternative medicine used by cancer patients in Korea. J Korean Acad Adult Nurs 2006;18:92–101.
12. Kim KS, Kim SH, Eo WK, Cheon SH, Eo SK, Jo HJ. Clinical research methodology for traditional Korean medicine treatment of lung cancer : Evidence based approach. J Oriental Medical Classics 2010;23(4):39–62.
13. Korean Asociation for the Study of Lung Cancer. Korean clinical practice guidelines for lung cancer Seoul: Korean Asociation for the Study of Lung Cancer; 2010. p. 1–134.
14. Kim SH, Namgung MA, Chang YS, Jeong SK, Kim JS, Yoon SW, et al. Study on Development of Assessment Guideline and Endpoints for Clinical Trial with Antitumor Natural Products. Korean J Oriental Physiology & Pathology 2006;20(6):1678–1727.
15. Chung MA. Guideline on evaluation of clinical trial of anticancer drugs Seoul: The Pharmaceutical Society of Korea; 2006. p. 145.
16. Drug Evaluation Department Oncology and Antimicrobial Products Division. Guidelines for clinical testing of anti-cancer drugs and non-clinical test data for approval of items Cheongju: Korea Food & Drug Administration; 2010. p. 1–13.
17. Lee SH, Han ES, Kim SH, Yun KE, Eom JE, Park SR, et al. Guidelines for clinical trial of anti-cancer drugs Cheongju: National Institute of Food and Drug Safety Evaluation; 2015. p. 1–31.
18. Lee SH, Han ES, Kim SH, Yun KE, Eom JE, Park SR, et al. Guidelines for non-clinical trial of anti-cancer drugs Cheongju: National Institute of Food and Drug Safety Evaluation; 2015. p. 1–13.
19. Lee SH, Han ES, Kim SH, Yun KE, Park SR, Kim DH, et al, ; National Institute of Food and Drug Safety Evaluation. Guidelines for Exemption of Anticancer Drug Data in Bridging Study Cheongju: National Institute of Food and Drug Safety Evaluation; 2016. p. 1–26.
20. Lee NH, Lee SD, Kim HS, Kim BS, Kang MS, Lee IS, et al. Guideline for the use of clinical trial medicines for therapeutic purposes Cheongju: Ministry of Food and Drug Safety; 2018. p. 1–47.
21. Lee HJ, Kim JH, Kim YK, Park CM, Chin AY, Jeong YJ. Korean Society of Thoracic Radiology Guideline for Lung Cancer Screening with Low-Dose CT. J Korean Soc Radiol 2012;67(5):349–365.
22. Shin SG. Clinical trial status and prospect of domestic drug Seoul: Korea Health Industry Development Institute; 2006. p. 7–14.
23. Shin HK, Kang JS, Kim YC, Lee KG, Yu YB, Bae SH. A Study on the clinical trial guideline of herbal medical drug(II) Seoul: Ministry of Food and Drug Safety; 2005. p. 1–538.
24. Ko SG, Jeong SK, Kwon DR, Seon SH, Ko HY, Jang BH, et al. Research on outcome indicators for clinical trials of herbal medicinal products Seoul: Ministry of Food and Drug Safety; 2006. p. 16–132.
25. Jang SY, Cho JH, Oh MH, Kim GE, Baek JH, Lee JP, et al. General considerations in clinical trials of herbal medicine preparations Seoul: Ministry of Food and Drug Safety; 2007. p. 1–173.
26. Kim DC, Park JY, Moon HJ, Kang IH, Kim JY, Kim HM, et al. Quality guidelines of herbal medicine for clinical trial Cheongju: National Institute of Food and Drug Safety Evaluation; 2017. p. 1–27.
27. Du QC, Yang KZ, Sun XF. Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 in treating patients of non-small cell lung cancer at peri-operational stage. Chin J Integr Med 2009;15(3):184–188.
28. Dou YQ, Yang MH, Wei ZM, Xiao C, Yang XH. The study of early application with Dixiong Decoction(地芎汤) for non-small cell lung cancer to decrease the incidence and severity of radiation pneumonitis: A prospective, randomized clinical trial. Chin J Integr Med 2010;16(5):411–416.
29. Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol 2012;29:1656–62.
30. Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial. Complement Ther Med 2016;24:55–62.
31. Xue D, Han S, Jiang S, Sun H, Chen Y, Li Y, et al. Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer. Med Oncol 2015;32:114.
32. Xu ZY, Jin CJ, Zhou CC, Wang ZQ, Zhou WD, Deng HB, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol 2011;137:1117–22.
33. Wu WY, Yang XB, Deng H, Long SQ, Sun LS, He WF, et al. Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine. Chin J Integr Med 2010;16(5):406–410.
34. Benveniste MF, Welsh J, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, et al. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. Radiol Clin North Am 2018;56(3):471–483.
35. Joshi SS, Maron SB, Catenacci DV. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol 2018;14(5):417–430.
36. Ji NF, Yao LS, Li Y, He W, Yi KS, Huang M. Polysaccharide of Cordyceps sinensis enhances cisplatin cytotoxicity in non-small cell lung cancer H157 cell line. Integr Cancer Ther 2011;10(4):359–367.
37. Jeong TY, Lee YW, Cho JG, Yoo HS. Analysis of Clinical Characteristics for 899 Cancer Patients Treated at an Oriental Hospital. Korean J Orient Int Med 2010;31(1):102–112.
38. The Evidence-Based Medicine Working Group. User’s Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice second editionth ed. AMA Press; 2002. p. 5–15.
39. Lee YM. Introduction to Evidence Based Medicine. Vascular Specialist International 2003;19(2):212–219.
40. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561–566.
41. Bledsoe TJ, Nath SK, Decker RH. Radiation Pneumonitis. Clin Chest Med 2017;38(2):201–208.
42. McDonald S, Rubin P, Phillips TL, et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995;31(5):1187–1203.
43. Eom SK. Disease recognition of tumor, bump or mass until Han Dynasty. The Journal Of Korean Medical Classics 2008;21(2):39–48.
44. Brierley J, Gospodarowicz M, O’Sullivan B. The principles of cancer staging. Ecancermedicalscience 2016;10:ed61.
45. Kim JY, Yoo HS, Cho JH. A Preliminary Study for Development of Clinical Practice Guidelines of Korean Medicine in Colorectal Cancer. Journal of Haehwa Medicine 2016;24(2):65–82.
46. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. How quality of life data contribute to our understanding of cancer patients’ experiences? A study of patients with lung cancer. Quality of Life Research 2003;12(2):157–166.
47. Cho JH, Son CG, Lee YW, Yoo HS, Seong JH, Kim SY. Current Status of Studies on Cancer-Related Quality of Life Instruments. Korean J Orient Int Med 2006;27(1):84–91.
48. Kim HY. Tumor response assessment (WHO vs. RECIST) and problems. J Clin Cancer Res 2007;1(2):1–6.
49. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer. ELCAPA study. J Clin Oncol 2011;29(27):3636–3642.
50. Lee NH, Cho JH, Son CG, Yoo HS, Lee YW, Yoon DH, et al. Analysis of Studies on Quality of Life according to Cancer Types and Symptoms. Korean J Orient Int Med 2006;27(3):555–560.
51. Jeon BM, Lee NH. Evaluation of the safety information of the client requesting pharmaceutical clinical trials and considerations for reporting Seoul: Ministry of Food and Drug Safety; 2017. p. 1–14.